Cybin to Rebrand as Helus Pharma and Shift U.S. Listing to Nasdaq
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Cybin ( (TSE:CYBN) ).
Cybin Inc. will transfer its U.S. stock exchange listing from NYSE American to the Nasdaq Global Market, with trading on Nasdaq expected to begin January 5, 2026 under a new ticker, “HELP,” as the company adopts the business name Helus Pharma in both the U.S. and on Cboe Canada. Management positions the move as a key step in its evolution into a global pharmaceutical player, aligning the mental-health drug developer with a larger peer group on Nasdaq and potentially increasing its visibility among investors as it advances late-stage clinical programs in depression and anxiety.
The most recent analyst rating on (TSE:CYBN) stock is a Buy with a C$55.00 price target. To see the full list of analyst forecasts on Cybin stock, see the TSE:CYBN Stock Forecast page.
Spark’s Take on TSE:CYBN Stock
According to Spark, TipRanks’ AI Analyst, TSE:CYBN is a Underperform.
Cybin’s stock score is significantly impacted by its lack of revenue and continuous financial losses, resulting in a low valuation score. While technical indicators are neutral, positive corporate events indicate potential for future growth. However, current financial challenges remain the dominant concern.
To see Spark’s full report on TSE:CYBN stock, click here.
More about Cybin
Cybin Inc., soon to be doing business as Helus Pharma, is a clinical-stage pharmaceutical company focused on developing next-generation treatments for mental health conditions such as major depressive disorder and generalized anxiety disorder. The company’s pipeline includes CYB003, now in Phase 3 as an adjunctive treatment for major depressive disorder with U.S. FDA Breakthrough Therapy Designation, and CYB004 in Phase 2 for generalized anxiety disorder, alongside a broader research portfolio of investigational compounds. Founded in 2019, Cybin operates in Canada, the United States, the United Kingdom and Ireland, targeting the large unmet need in mental healthcare through novel, durable-acting drugs.
Technical Sentiment Signal: Hold
Current Market Cap: C$1.92M
Find detailed analytics on CYBN stock on TipRanks’ Stock Analysis page.
Disclaimer & DisclosureReport an Issue
